ipilimumab
bms
['ipilimumab', 'melanoma']
icymi: late-breaking data from #esmo22 shows til therapy leads to 50% reduction in pfs measures over ipilimumab in phase 3 study in unresectable #melanoma. read more: 
CGTLive™ delivers quality and relevant information to healthcare professionals on cell, gene, regenerative, and engineered medicines to ultimately improve care.